Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM

Table 6

Distribution of final scores of suspected agents in DILI cases using the updated RUCAM [6].

	Total frequencies	Highly probable (score ≥9)	Probable (score 6∼8)	Possible (score 3∼5)	Unlikely (score 1∼2)	Excluded (score ≤0)
SR/IR
HD-MTX	38	5 (13.2%)	31 (81.6%)	2 (5.3%)	0 (0.0%)	0 (0.0%)
HR
DXM	15	0 (0.0%)	0 (0.0%)	3 (20.0%)	12 (80.0%)	0 (0.0%)
VCR	9	0 (0.0%)	0 (0.0%)	9 (100.0%)	0 (0.0%)	0 (0.0%)
HD-MTX	12	0 (0.0%)	12 (100.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
CTX	7	0 (0.0%)	0 (0.0%)	7 (100.0%)	0 (0.0%)	0 (0.0%)
HD-Ara-C	10	1 (10.0%)	6 (60.0%)	0 (0.0%)	0 (0.0%)	3 (30.0%)
PEG-ASP	15	0 (0.0%)	2 (13.3%)	0 (0.0%)	0 (0.0%)	13 (86.7%)
VDS	3	0 (0.0%)	0 (0.0%)	3 (100.0%)	0 (0.0%)	0 (0.0%)
IFO	5	0 (0.0%)	0 (0.0%)	5 (100.0%)	0 (0.0%)	0 (0.0%)
DNR	5	0 (0.0%)	0 (0.0%)	3 (60.0%)	0 (0.0%)	2 (40.0%)
VP-16	3	0 (0.0%)	0 (0.0%)	2 (66.7%)	0 (0.0%)	1 (33.3%)

RUCAM, Roussel Uclaf Causality Assessment Method; SR/IR, standard risk/intermediate risk; HR, high risk; HD-MTX, high-dose methotrexate; DXM, dexamethasone; VCR, Vincristine; CTX, cyclophosphamide; HD-Ara-C, high-dose cytarabine; PEG-ASP, pegylated asparaginase; VDS, vindesine; IFO, ifosfamide; DNR, daunorubicin; VP-16, etoposide.